● SCTX shares fell 16.23%, pulling back from the low $30s after more than doubling from its $15 IPO price in late July.
Profusa, Inc. (NASDAQ:PFSA) jumped 9.17% in a session that underscored just how volatile the micro-cap medical-technology name has become. The biosensor developer has swung violently in both directions through August, and the latest gain looks more like a bounce within a turbulent stretch than …
● PRPL shares fell 11.55% after second-quarter 2026 netRevenueof roughly $98.3 million came in below the prior year alongside a loss per share of about $0.74.
Hyperliquid Strategies (NASDAQ:PURR), a publicly traded treasury company built around the HYPE token, surged 11.56% as investors continued to treat the stock as a listed proxy for one of the crypto market's most talked-about assets.
MapLight Therapeutics (NASDAQ:MPLT), a newly public central-nervous-system biotech, climbed roughly 10% as investors continued to reassess a name that has whipsawed since its market debut. The stock has become a focal point for traders drawn to the volatile intersection of neuroscience and clinical-trial catalysts.
Everspin Technologies (NASDAQ:MRAM) climbed 9.23% in a session that saw money rotate back into small-capitalization semiconductor names, lifting a stock that has spent much of 2026 quietly rebuilding its case with investors. The move stands out because Everspin is not a story built on …
● NXTT shares fell 13.21%, tracking softerBitcoinsentiment and lingering wariness toward the company's aggressively reworked capital structure.
Oklo (NYSE:OKLO), the advanced-nuclear developer backed by prominent Silicon Valley investors, jumped roughly 11% as a broad rally in nuclear stocks coincided with a major regulatory milestone for the company's test-reactor program.
Laird Superfood (NYSE American:LSF) advanced 9.02%, extending gains that followed a transformative second-quarter report. The plant-based food and beverage company has shifted from a slow-growth natural-products story into a much larger business through acquisitions, and the market has been re-rating the stock as the …
Pulmonx (NASDAQ:LUNG), the medical-device maker behind the Zephyr Endobronchial Valve for severe emphysema, rose 9.65% as investors reassessed a stock that has been deeply out of favor for much of the past two years.